It has been demonstrated that the tri-specific CD19-CD20-CD22-targeting CAR-T cells could rapidly eliminate B cell lymphoma in a preclinical study (181), and BAFF ligand-based CAR-T cells simultaneously target three receptors, including BAFF-R, BCMA, and TACI (182). The gene discussed is TNFRSF17; the disease is B-cell non-Hodgkin lymphoma.